comprehensive -WSS

comprehensive

author：focus 2025-10-01 22:16:30 - browse：3

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Health and fitness trackers are measuring the wrong things

WSS

What American doctors can learn from their Israeli counterparts

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Caregivers of transplant patients call for more support, training

New Medicare drug pricing powers could soon be upended in court

Illumina names Agilent executive as new CEO

AstraZeneca chief proposes a novel edit to the drug pricing bill

focus

comprehensive

entertainment

Apple is now the first public company to be valued at $3 trillion

Stem cell treatment guidelines are released by FDA

Drug repurposing or repositioning? The language matters

New menopause drug shows promise in relief for hot flashes

Trump demands the U.S. pay no more for drugs than other countries … again

Health and fitness trackers are measuring the wrong things

Medical records are filled with copy

Three issues to watch in global health in 2024

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Humana sues Biden admin over Medicare Advantage audit rule

entertainment

New Medicare drug pricing powers could soon be upended in court

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Generative AI mines health records to identify patients’ social needs

Doulas covered by Medicaid under New York's new plan

Stem cell treatment guidelines are released by FDA

Snackable artificial intelligence, expert AI, and the pharma industry

leisure time

Wikipedia

Wikipedia

hotspot